
NeuroMetrix NURO
Annual report 2024
added 03-31-2025
NeuroMetrix General and Administrative Expenses 2011-2026 | NURO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses NeuroMetrix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.33 M | 4.96 M | 4.39 M | 3.99 M | 3.52 M | 5.92 M | 4.84 M | 5.69 M | 4.87 M | 5.5 M | 4.73 M | 4.23 M | 4.74 M | 5.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 M | 3.52 M | 4.91 M |
Quarterly General and Administrative Expenses NeuroMetrix
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.31 M | 1.62 M | 1.77 M | - | 1.21 M | 1.24 M | 1.39 M | - | 1.1 M | 1.18 M | 1.19 M | - | 966 K | 1.28 M | 1.01 M | - | 763 K | 678 K | 1.25 M | - | 1.46 M | 1.56 M | 1.62 M | - | 1.02 M | 1.17 M | 1.8 M | - | 1.26 M | 1.25 M | 1.42 M | - | 1.17 M | 1.29 M | 1.42 M | - | 1.39 M | 1.22 M | 1.55 M | - | 1.31 M | 1.15 M | 1.15 M | - | 1.01 M | 992 K | 1.23 M | - | 1.15 M | 1.38 M | 1.19 M | - | 1.2 M | 1.3 M | 1.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.8 M | 678 K | 1.26 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
2.89 B | $ 16.55 | -0.63 % | $ 8.49 B | ||
|
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
251 M | $ 74.08 | -0.76 % | $ 40.4 B | ||
|
The Cooper Companies
COO
|
1.63 B | $ 68.85 | -2.06 % | $ 13.7 B | ||
|
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | ||
|
electroCore
ECOR
|
38.2 M | $ 6.76 | -4.05 % | $ 57.3 K | ||
|
Ekso Bionics Holdings
EKSO
|
9.99 M | $ 9.14 | -6.26 % | $ 22.2 M | ||
|
BioLife Solutions
BLFS
|
40.5 M | $ 18.62 | -3.37 % | $ 858 M | ||
|
Glaukos Corporation
GKOS
|
224 M | $ 116.32 | -0.36 % | $ 5.63 B | ||
|
AtriCure
ATRC
|
311 M | $ 29.09 | -0.34 % | $ 1.39 B | ||
|
Haemonetics Corporation
HAE
|
437 M | $ 59.06 | 1.1 % | $ 2.97 B | ||
|
Harvard Bioscience
HBIO
|
17.7 M | $ 5.31 | -3.95 % | $ 236 M | ||
|
iRhythm Technologies
IRTC
|
493 M | $ 116.43 | -0.68 % | $ 3.73 B | ||
|
Repro Med Systems
KRMD
|
23.4 M | $ 4.26 | - | $ 197 M | ||
|
Masimo Corporation
MASI
|
744 M | $ 178.36 | -0.07 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
8.46 M | $ 2.29 | -2.97 % | $ 105 M | ||
|
Milestone Scientific
MLSS
|
11.6 M | $ 0.29 | 1.38 % | $ 23.8 M | ||
|
Envista Holdings Corporation
NVST
|
1.16 B | $ 24.99 | -3.21 % | $ 4.2 B | ||
|
Pro-Dex
PDEX
|
4.84 M | $ 50.03 | 3.09 % | $ 164 M | ||
|
ResMed
RMD
|
739 M | $ 223.41 | -0.62 % | $ 32.6 B | ||
|
ICU Medical
ICUI
|
625 M | $ 121.46 | -1.24 % | $ 2.99 B | ||
|
Retractable Technologies
RVP
|
12.8 M | $ 0.72 | 1.45 % | $ 21.6 M | ||
|
InfuSystem Holdings
INFU
|
46.1 M | $ 9.41 | -0.21 % | $ 194 M | ||
|
Isoray
ISR
|
30.2 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
2.38 B | $ 450.18 | -0.53 % | $ 161 B | ||
|
STAAR Surgical Company
STAA
|
85.8 M | $ 21.38 | 2.0 % | $ 1.06 B | ||
|
Stereotaxis
STXS
|
17.8 M | $ 1.86 | -1.59 % | $ 169 M | ||
|
LeMaitre Vascular
LMAT
|
42 M | $ 109.87 | 0.65 % | $ 2.49 B | ||
|
Teleflex Incorporated
TFX
|
720 M | $ 115.67 | 0.51 % | $ 5.16 B | ||
|
Merit Medical Systems
MMSI
|
455 M | $ 68.33 | 0.77 % | $ 4.04 B | ||
|
Utah Medical Products
UTMD
|
7.88 M | $ 63.75 | 1.3 % | $ 207 M | ||
|
Predictive Oncology
POAI
|
25.9 M | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
32 M | $ 19.27 | -16.0 % | $ 1.3 B | ||
|
West Pharmaceutical Services
WST
|
394 M | $ 257.61 | 0.25 % | $ 18.6 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.44 B | $ 11.46 | -1.55 % | $ 2.29 B | ||
|
STERIS plc
STE
|
1.33 B | $ 218.23 | -0.8 % | $ 21.5 B | ||
|
AngioDynamics
ANGO
|
42.1 M | $ 9.44 | -4.07 % | $ 386 M | ||
|
Becton, Dickinson and Company
BDX
|
5.28 B | $ 154.93 | -0.2 % | $ 44.6 B | ||
|
Nephros
NEPH
|
8.91 M | $ 2.73 | -4.55 % | $ 28.4 M | ||
|
OraSure Technologies
OSUR
|
47.7 M | $ 3.03 | -1.79 % | $ 223 M | ||
|
Repligen Corporation
RGEN
|
219 M | $ 114.82 | -1.82 % | $ 6.4 M |